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Background: Airway remodeling is a proposed mechanism that underlies the persistent loss of lung function
associated with childhood asthma. Previous studies have demonstrated that human lung fibroblasts (HLFs) co-cultured
with primary human bronchial epithelial cells (BECs) from asthmatic children exhibit greater expression of extracellular
matrix (ECM) components compared to co-culture with BECs derived from healthy children. Myofibroblasts represent a
population of differentiated fibroblasts that have greater synthetic activity. We hypothesized co-culture with asthmatic
BECs would lead to greater fibroblast to myofibroblast transition (FMT) compared to co-culture with healthy BECs.
Methods: BECs were obtained from well-characterized asthmatic and healthy children and were proliferated and
differentiated at an air-liquid interface (ALI). BEC-ALI cultures were co-cultured with HLFs for 96 hours. RT-PCR
was performed in HLFs for alpha smooth muscle actin (α-SMA) and flow cytometry was used to assay for α-SMA
antibody labeling of HLFs. RT-PCR was also preformed for the expression of tropomyosin-I as an additional marker
of myofibroblast phenotype. In separate experiments, we investigated the role of TGFβ2 in BEC-HLF co-cultures
using monoclonal antibody inhibition.
Results: Expression of α-SMA by HLFs alone was greater than by HLFs co-cultured with healthy BECs, but not different
than α-SMA expression by HLFs co-cultured with asthmatic BECs. Flow cytometry also revealed significantly less α-SMA
expression by healthy co-co-cultures compared to asthmatic co-cultures or HLF alone. Monoclonal antibody inhibition
of TGFβ2 led to similar expression of α-SMA between healthy and asthmatic BEC-HLF co-cultures. Expression of
topomyosin-I was also significantly increased in HLF co-cultured with asthmatic BECs compared to healthy BEC-HLF
co-cultures or HLF cultured alone.
Conclusion: These findings suggest dysregulation of FMT in HLF co-cultured with asthmatic as compared to
healthy BECs. Our results suggest TGFβ2 may be involved in the differential regulation of FMT by asthmatic BECs.
These findings further illustrate the importance of BEC-HLF cross-talk in asthmatic airway remodeling.
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Asthma is the most common chronic disease in children,
affecting at least 6 million children and causing greater
than 7 million physician visits and 200,000 hospitaliza-
tions annually in the United States alone [1]. In recent
years, our understanding of the pathogenesis of persist-
ent bronchial asthma has advanced significantly. We
now appreciate that the obstructive lung disease in-
curred as a result of asthma occurs during childhood [2]
and does not improve as a child ages into adulthood [3]
or with treatment using current asthma therapies [4-6].
Contemporary views of asthma pathophysiology now
include disordered wound repair and associated airway
remodeling as chief components underlying the ob-
structive lung disease that is associated with asthma in
addition to chronic inflammatory changes [7]. Further-
more, we now understand that the airway epithelium
undergoes significant structural changes early in asthma.
Given that it is the first point of contact between the
host airways and the environment, a new paradigm of
asthma pathogenesis has emerged to potentially explain
asthma progression and airway remodeling, wherein on-
going injury, irritation, and/or viral infection of airway
epithelial cells results in disordered wound repair, in-
cluding disordered epithelial modulation of lung fibro-
blast and airway smooth muscle activity [8].
Multiple previous studies have identified sub epithelial
thickening and deposition of extra cellular matrix (ECM)
as common features of airway biopsies from both adults
and children [9,10]. Recent data from in vitro studies in
our laboratory has demonstrated that human lung fibro-
blasts (HLFs) co-cultured with primary human bronchial
epithelial cells (BECs) produce greater quantities of
ECM components when the co-cultures were performed
with BECs obtained from asthmatic children, suggesting
altered regulation of the epithelial-fibroblast cross-talk
[11]. While lung fibroblasts have been extensively stud-
ied in the context of pulmonary fibrosis [12], their inher-
ent role in asthmatic airway remodeling is just beginning
to be elucidated [13,14]. Previous studies have demon-
strated that mesenchymal cells such as fibroblasts are
the predominant source of many ECM proteins. The lat-
ter is particularly true for fibroblasts that have differenti-
ated into a myofibroblast phenotype [15,16], i.e. alpha
smooth muscle actin (α-SMA) expressing fibroblasts.
Myofibroblasts are known to be the primary source of
type I and III collagen in fibrotic lesions and this is a
consequence of a phenotype differentiation that is
dependent on stimulation by transforming growth factor
beta (TGFβ) [17-19]. Furthermore, myofibroblasts repre-
sent a contractile phenotype that may also directly par-
ticipate in scar formation and contraction and this may
be enhanced in primary bronchial fibroblasts derived
from asthmatics [20]. BECs have been demonstrated toinfluence fibroblast-to-myofibroblast transition (FMT),
possibly via paracrine signaling [21]; however, the role of
primary BECs derived from asthmatic children versus
those obtained from healthy children in FMT has not
been described.
In order to further investigate the role that BECs play
in the regulation of FMT, we employed a co-culture
model to evaluate the differences in HLF cultures that
were either co-cultured with healthy or asthmatic BECs.
We hypothesized that the HLFs co-cultured with primary
BECs derived from asthmatic children would display a
greater degree of FMT compared to HLFs co-cultured
with BECs derived from healthy children. Furthermore,
the presence of greater numbers of myofibroblasts could
account for the enhanced deposition of ECM that has
been previously described in our model system and may
further explain the degree of airway remodeling that has
been reported in asthmatic children.
Methods
Subjects
Atopic asthmatic and healthy non-atopic non-asthmatic
children ages 6–18 years who were undergoing an elect-
ive surgical procedure requiring endotracheal intubation
and general anesthesia were recruited for this study. A
detailed medical history was obtained at enrollment to
ensure that participants met the following inclusion and
exclusion criteria. Children with asthma had at least a
1 year history of physician-diagnosed asthma, physician
documented wheezing in the 12 months prior to study
enrollment, used a short-acting beta-agonist (albuterol) ≥
twice a month or were taking a daily inhaled cortico-
steroid or leukotriene receptor antagonist, and were
born at ≥ 36 weeks gestation. Healthy subjects were born
at ≥ 36 weeks gestation, had no history of asthma, react-
ive airway disease, chronic daily cough, or physician-
diagnosed obstructive lung disease, and no history of
prior treatment with a systemic or inhaled corticoster-
oid, short-acting beta-agonist (albuterol), or oxygen.
Children with asthma had one or more of the following
atopic features: history of a positive skin prick test or
positive radioallergosorbent testing (RAST) for a com-
mon aeroallergen (discussed below), elevated serum IgE
(>100 IU/mL), history of physician-diagnosed and
treated allergic rhinitis, history of physician-diagnosed
and treated atopic dermatitis. Healthy subjects lacked a
history of any of the above atopic features and were
excluded if they had any other atopic comorbidity.
From each subject, a blood sample was drawn and
used to measure total serum IgE and RAST allergen-
specific IgE to dust mites (D. farina and D. pteronyssinus),
cat epithelium, dog epithelium, alternaria tenuis, aspergil-
lus fumigatus, and timothy grass. The fraction of exhaled
nitric oxide (FENO) was measured according to American
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nitric oxide analyzer (Aerocrine®, Sweden) [22]. Forced vital
capacity (FVC), forced expiratory volume in 1 second
(FEV1), and forced expiratory flow between 25% and 75%
of FVC (FEF25–75) were measured according to ATS guide-
lines using a VMAX® series 2130 spirometer (VIASYS
Healthcare, Hong Kong). Spirometry was repeated 15 mi-
nutes following administration of 2 puffs of albuterol in
children with asthma.
Written consent was obtained from parents of subjects
and assent was obtained for children ≥ age 7 years. The
Seattle Children’s Hospital Institutional Review Board
approved this study.Epithelial cell isolation, proliferation, and differentiation
Immediately after the endotracheal tube was secured
three bronchial epithelial cell samples were obtained
from subjects while under general anesthesia using
4 mm Harrell® unsheathed bronchoscope cytology brushes
(CONMED® Corporation). As described by Lane et al.
[23], the unprotected brush was inserted through an endo-
tracheal tube, advanced until resistance was felt, and
rubbed against the airway surface for 2 seconds. Cells were
seeded onto T-25 cell culture flasks pre-coated with type I
collagen and proliferated under submerged culture
conditions. Using passage 2 cells, epithelial cells were
differentiated at an air-liquid interface (ALI) using
methods previously described by our lab [24].
BEC-fibroblast co-cultures
HLFs from a healthy child were obtained from a com-
mercial vender (Lonza, Walkersville, MD) and the same
passage of HLFs were used for all co-culture experi-
ments. HLF cultures were established using a Fibroblast
Cell Media BulletKit™ (FGM) per Lonza recommenda-
tions. HLF were seeded at a density of ~2,500 cells/cm2
in 12-well Collagen I BD BioCoat™ plates (Becton
Dickinson, Bedford, MA) and incubated for 7 days to
achieve a confluent monolayer prior to initiation of
BEC-HLF co-cultures. Media changes of FGM occurred
at 48 hour intervals. At 48 hours prior to experimental
Day 0, the HLF media was replaced with co-culture
media (1:1 FGM and PneumaCult ALI Maintenance
Media). ALI transwells were placed in co-culture with
the HLF cells at experimental Day 0 by transferring the
transwell inserts to the well plates containing the estab-
lished HLF cultures. The transwells inserts containing
the BEC ALI culture were in close proximity to the sub-
merged HLF cultures contained in the basolateral cham-
ber (~1 mm between the well plate and the permeable
transwell bottom) and shared the same media. The co-
culture media in the basolateral chamber was changed
every 24 hours and stored at −80°C for subsequentanalysis. The media and cells were collected for studies
96 hours following initiation of co-culture experiments.
RNA extraction and real-time PCR
Total RNA was isolated from HLF cells co-cultured with
BEC’s grown at an ALI. Three wells from each experi-
mental condition were harvested and pooled to isolate
RNA using the RNAqueous kit for total RNA purifica-
tion from Ambion®-Applied Biosystems (Austin, TX).
RNA concentration and integrity were determined using
the Agilent® 2100 Bioanalyzer system and Agilent® RNA
6000 Nano Chips (Agilent® Technologies, Foster City,
CA). RNA samples (1 μg) with a RNA integrity number
(RIN) ≥ 8 were reverse transcribed with MMLV reverse
transcriptase with a combination of random hexamers
and oligo-dTs using the SuperScript® VILO cDNA Synthe-
sis Kit (Life Technologies, Grand Island, NY). Samples
were diluted up to a final volume of 100 μl (10 ng/μl).
Semi-quantitative real-time qPCR was performed using
validated TaqMan® probes (Life Technologies, Grand
Island, NY) for alpha smooth muscle actin (α-SMA).
Assays were performed using the TaqMan® Fast Advanced
Master Mix reagents and accompanying protocol and the
Applied Biosystems StepOnePlus™ Real-Time PCR System
with StepOne Software v2.2.2 (Life Technologies, Grand
Island, NY).
Immunohistochemistry (IHC)
Sterilized 12 mm round glass coverslips were coated
with type I collagen and placed in the bottom of one of
the replicate chambers of the 12 well plates prior to
seeding the HLFs. Following 96 hrs of co-culture, the
coverslips were carefully removed and placed in a separ-
ate 12 well plate for IHC. Coverslips containing cells
were then washed 3 times in room temperature PBS to
remove residual media and were then fixed with 50:50
methanol and acetone at 20°C for 10 minutes. Coverslips
were then washed with PBS and blocked with 10% FBS
for 30 minutes. Following this, coverslips were washed
again with PBS and then incubated with an α-SMA-FITC
primary antibody (clone 1A4, 1:500; Sigma Aldrich, St
Louis, MO). Coverslips were then washed in PBS three
times and were then mounted on to slides using ProLong®
Gold antifade reagent with DAPI (Life Technologies,
Grand Island, NY). Images were acquired using an auto-
mated Leica DM6000B fluorescent microscope (Leica
Microsystems, Wetzlar, Germany) in 7 × 7 grids at 400 ×
and stitched together using LASAF software to provide
higher resolution images of larger areas of tissue.
In order to enumerate the number of cells present per
field, anaylsis of DAPI stained nuclei was performed in
addition to α-SMA staining described above. Stitched
images were inverted, cropped to identical pixel densities
(9000 × 6000), and saved as binary image files (Adobe
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imported into ImageJ (National Institutes of Health,
Bethesda, MD) where the images were processed using
the automatic threshold setting to mitigate any sampling
bias. Positive stained nuclei were counted using the particle
analysis feature.
Flow cytometry
Following the 96 hour co-culture exposure HLFs from
each experimental group were mechanically detached
from the culture wells and suspended in PBS. Samples
were snap frozen in liquid nitrogen so that samples from
each group were run in parallel. Before the flow cytome-
try protocol began, the cells were quickly thawed and
then centrifuged for 5 minutes at 200 × g and suspended
in PBS for two washings. The cells were then fixed and
permeabilized in ice cold 50:50 methanol/acetone for
10 minutes. Subsequently the cells were washed twice
with Flow Cytometry Staining Buffer (Cat. 00–4222,
eBioscience, San Diego, CA). After these washes the
HLF were incubated with anti-α-SMA conjugated to
FITC (clone 1A4, 1:1000; Sigma Aldrich, St Louis, MO)
for 45 minutes at room temperature negative controls
were maintained in parallel and were not stained in this
step. Cells were then twice washed again with Flow
Cytometry Staining Buffer and the data was then ac-
quired with a LSR II flow cytometer (Becton Dickinson,
Bedford, MA). Both negative controls (unstained HLF)
and positive controls (>2 week old HLF cultures) were
used to set gating parameters for data acquisition. Data
was analyzed following acquisition with FlowJo 8 (Treestar
INC, Ashland, OR).
Monoclonal antibody inhibition studies
HLF cultures at 7 days were exposed to TGFβ2 (1 μg/
mL, R&D Systems, Minneapolis, MN), monoclonal neu-
tralizing antibody (Mab) to TGFβ2 (10 μg/mL, Sigma Al-
drich, St Louis, MO), and/or PGE2 (40 μg/mL, Cayman
Chemical Company, Ann Arbor, MI) for 48 hrs. Given
the short half-life of PGE2, media was refreshed with
40 μg/mL every 6 hours during experiments. RNA was
extracted after 48 hours of exposure and expression of
α-SMA was assessed using qPCR. In separate experi-
ments, HLF co-cultured with healthy or asthmatic BEC
cultures were exposed every 24 hours to TGFβ2 Mab
(10 μg/mL, Sigma Aldrich, St Louis, MO) for 96 hours,
at which time RNA was extracted and expression of α-
SMA was assessed using qPCR.
Gene expression was normalized to GAPDH in all
experiments.
Statistical analysis
For clinical parameters including age, lung function and
FENO, the paired t-test was used for comparisonsbetween asthmatic and healthy subjects as data was
normally distributed within each subject group. The
Wilcoxon signed-rank test was used to compare gender
and IgE levels because the distributions among asthmatic
subjects were non-normally distributed. For RT-PCR
studies, the relative expression of α-SMA was normal-
ized using glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) as a non-regulated reference gene. Analyses
of real-time qPCR results were performed using GenEx
version 5.0.1 (MultiD Analyses AB, Göteborg, Sweden)
based on methods described by Pfaffl [25]. Statistical
significance was set at p < 0.05. For flow cytometry
data, pairwise comparisons across the groups were used
for non-parametric data (Mann Whitney U) with a
significance level set at p < 0.05. For cell enumeration
data, the Kruskal–Wallis test was used to make com-
parisons among the groups, as this data was not nor-
mally distributed. Statistical analyses of clinical data,
flow cytometry data, and cell enumeration data were
performed using Prism® 6.0 software (GraphPad Software
Inc., San Diego, CA).
Results
Lower airway cells were obtained by bronchial brushings
from 10 healthy and 10 asthmatic children as defined by
the inclusion criteria discussed in the methods section.
Primary BEC cultures were derived from these samples
and used for all portions of the experiment. Summary
data for the patient characteristics is displayed in Table 1.
The ages of the subjects were comparable (healthy 10.3
+/− 3.6 vs. asthmatic 11.7 +/− 3.4; p = 0.4); however, our
asthmatic group contained a greater number of males.
The majority of our asthmatic subjects were using daily
inhaled corticosteroids (ICS; 90%). Additionally, most of
the asthmatic subjects had positive RAST testing to a
specific aeroallergen (90%). Asthmatic subjects also dis-
played a significantly higher serum IgE compared to
healthy subjects (916 IU/mL in asthmatic subjects vs
21.3 IU/mL in healthy subjects; p < 0.0005). While most
parameters of the pulmonary function tests were com-
parable between the groups including FENO levels (14.9
+/− 8.8 vs. 9.3 +/− 4.6; p = 0.2), the FEV1/FVC ratio was
significantly lower in asthmatic as compared to healthy
subjects (83% +/− 5% vs. 89% +/− 4%, respectively; p =
0.04). In all, these findings are representative of the pa-
tient population seen at Seattle Children’s Hospital and
represent an asthmatic population with fairly mild
disease.
In order to characterize the trajectory of endogenous
FMT within our HLF cell lines, mRNA was isolated
along a time course study following seeding at day 1
(~25% confluent), day 3 (~60% confluent), and day 7
(100% confluent). Expression of α-SMA was used as a
surrogate for FMT and at day 7 following seeding was
Table 1 Characterization of subjects
Healthy Controls Asthmatics P value
(N = 10) (N = 10)
Age yrs. (SD) 10.3 (3.6) 11.7 (3.4) 0.4
Females (%) 60% 20% 0.07
History of Eczema (yes; %) 0 4 (40%) N/A
History of Allergic Rhinitis (yes; %) 0 9 (90%) N/A
Positive RAST (yes; %) 0 9 (90%) N/A
Use of inhaled steroids at enrollment (yes; %) 0 9 (90%) N/A
IgE IU/mL (SD) 21.3 (12.4) 916 (1616) 0.0005
FVC % predicted (SD) 101 (13.2) 100.7 (11.5) 0.9
FEV1/FVC Ratio (SD) 0.89 (0.04) 0.83 (0.05) 0.04
FEV1 % predicted (SD) 99.8 (14.5) 96.6 (12.1) 0.6
FEF25–75 % predicted (SD) 99 (20.4) 88 (18.5) 0.2
FENO ppb (SD) 9.3 (4.6) 14.9 (8.8) 0.2
RAST = radioallergosorbent testing; FVC = forced vital capacity; FEV1 = forced expiratory volume in 1 second; FEF25-75 = forced expiratory flow between 25% and
75% of expiration; SD = standard deviation.
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0.0001; Figure 1). Next, expression of α-SMA mRNA
was examined following 96 hours of co-culture with
either BECs derived from healthy children or BECs
derived from asthmatic children (Figure 2). Time con-
trols of HLF alone were maintained in parallel and are
shown for comparison. Expression of α-SMA mRNA by
HLFs co-cultured with healthy BEC was 1.9 fold lower
than HLF alone (p = 0.008). In contrast, HLFs co-
cultured with asthmatic BECs displayed no significantFigure 1 Time course of α-SMA expression in HLF cultures. The expres
through Day 7 (start of co-culture exposures). Expression of α-SMA at Day 7difference when compare to HLFs alone; however, the
asthmatic BEC-HLF co-cultures expressed 2-fold greater
α-SMA compared to healthy BEC-HLF co-cultures (p =
0.002).
Immunostaining of the HLF for α-SMA revealed quali-
tatively greater staining in the HLF alone group com-
pared to either the HLF co-cultured with healthy BEC or
asthmatic BEC. However, considerably greater staining
was observed in the HLF co-cultured with BEC derived
from asthmatic children (representative images aresion of α-SMA by HLF cultures is shown following initial seeding
of culture was 25 fold higher than Day 1 (p < 0.0001).
Figure 2 Expression of α-SMA mRNA following 96 hours of co-culture. Expression of α-SMA by HLFs cultured alone was 1.9 fold higher than
by HLFs co-cultured with healthy BECs (p = 0.008; *). α-SMA expression by HLFs co-cultured with asthmatic BECs was 2-fold higher than by HLFs
co-cultured with healthy BECs (p = 0.002; **). There was no difference in α-SMA expression between HLFs cultured alone and HLFs co-cultured
with asthmatic BECs.
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staining of the HLF for α-SMA, the same antibody that
was used for immunohistochemistry was also used for
flow cytometry experiments in a subset of samples (n = 4
per group). Flow cytometry staining for α-SMA in HLF
cells alone following the 96-hour experiment revealed
11.6% positively stained cells, which significantly was
greater than HLF co-cultured with healthy BEC (3.6%;
p < 0.03; Figure 4). Staining for α-SMA positive HLF
was greater in HLF co-cultured with asthmatic BECFigure 3 Immunostaining for α-SMA in HLF alone or co-cultured with
(Panel A), HLF Co-Cultured with heathy BECs (Panel B), and HLF Co-Cultured
counterstained for DAPI.compared to healthy BEC (p < 0.03). No significant dif-
ferences emerged between HLF cultured alone and
HLF co-cultured with asthmatic BEC.
In order to ascertain whether the findings of differen-
tial α-SMA staining in the above experiments was re-
lated to differing cell densities present in the HLF cell
cultures versus an alteration in the overall expression of
α-SMA, non-bias computer automated counts of DAPI
stained nuclei were also evaluated in the immunohisto-
chemistry sections (n = 10 per group). No significanthealthy or asthmatic BECs. Immunostaining for α-SMA in HLF Alone
with asthmatic BECs (Panel C) following 96 hr exposure. All sections are
Figure 4 Quantification of α-SMA positive cells by flow cytometry.
Flow cytometry for α-SMA (% positive) in HLF Alone, HLF Co-Cultured
with Heathy BECs, and HLF Co-Cultured with Heathy BECs following
96 hr exposure. Flow cytometry revealed 3.6% α-SMA positive cells in
the healthy co-culture group compared to 8.1% α-SMA positive cells in
the asthmatic co-culture group (p < 0.03) and 11.6% α-SMA positive cells
in the HLF alone (p < 0.03).
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observed among the groups (Figure 5).
In our previous studies, we have demonstrated greater
expression of active TGFβ2 in asthmatic BEC-HLF co-
cultures despite no significant differences in the expres-
sion of active TGFβ1 when compared to either healthy
BEC-HLF co-cultures or HLF alone [11]. To further
investigate the effects of TGFβ2 signaling in the present
study, HLF cultures were exposed to exogenous TGFβ2
with and without the addition of monoclonal anti-Figure 5 Quantification of total number of HLF cells in HLF
cultured alone compared to co-culture with healthy or asthmatic
BECs. Cell counts as demonstrated by software enumeration of DAPI
positive nuclei. No significant differences were observed among the
three HLF groups (n = 10 per group).TGFβ2 antibody (n = 6 per group). Administration of
exogenous TGFβ2 lead to a 17-fold increase in α-SMA
expression (p < 0.001; Figure 6). The addition of monoclo-
nal antibody to TGFβ2 ameliorated the TGFβ2-mediated
increase in α-SMA expression by about 50% (p < 0.01).
The addition of exogenous PGE2 led to an 80% reduc-
tion in α-SMA expression compared to untreated
HLFs (p < 0.01).
Furthermore, we then conducted experiments using a
subset of asthmatic and healthy BECs (n = 3 per group;
Figure 7) to test the effect of the addition of TGFβ2 neu-
tralizing monoclonal antibody to HLF co-cultured with
BECs. Similar to experiments outlined in Figure 2, ex-
pression of α-SMA by HLFs co-cultured with healthy
and asthmatic BECs was significantly less than by HLFs
alone. Expression of α-SMA by HLFs co-cultured with
healthy BECs was 40% lower than by HLFs co-cultured
with asthmatic BECs (p < 0.01). The addition of TGFβ2
neutralizing monoclonal antibody to healthy BEC-HLF
co-cultures did not significantly change expression of α-
SMA by HLFs, whereas the addition of TGFβ2 neutraliz-
ing monoclonal antibody to asthmatic BEC-HLF co-
cultures led to a 30% reduction in expression of α-SMA
by HLFs (p < 0.01).
In addition to the experiments conducted above in-
volving the examination of α-SMA expression, we also
examined the expression of tropomyosin-I as a second
marker of the myofibroblast phenotype (Figure 8). Inter-
estingly we did not observe an inherent up regulation of
tropomyosin-I in the HLF cultured alone. Expression of
tropomyosin-I was not significantly different between
HLF alone and HLF co-cultured with healthy BEC co-
cultures following 96 hours of co-culture. In contrast,
expression of tropomyosin-I in HLF co-cultured with
asthmatic BEC co-cultures was greater than HLF alone
or HLF co-cultured with healthy BEC (6.2 fold p < 0.004;
4.3 fold p < 0.03, respectively).
Discussion
In this study, we demonstrate for the first time that co-
culture of HLFs with BECs derived from a healthy
pediatric donor significantly down-regulates FMT in cul-
tured HLF cells. Furthermore, we demonstrate that co-
culture of the same HLF cell line with BECs derived
from asthmatic children does not produce the same de-
gree of FMT down-regulation. Conversely, these co-
cultured HLF have a comparable degree of FMT to HLF
cells cultured alone suggesting impaired regulatory
signaling from the asthmatic derived BECs. Differences
observed among the three HLF groups could not be
accounted for by alterations in the cell density suggest-
ing that the increased expression of α-SMA as a marker
of FMT was related to differential gene expression and
not altered cellular proliferation in the established HLF
Figure 6 Expression of α-SMA mRNA in HLF following exposure to TGFβ2, TGFβ2 monoclonal neutralizing antibody, and PGE2.. TGFβ2
exposure lead to a 17-fold increase in α-SMA expression (p < 0.001). This effect was decreased by nearly 50% with addition of TGFβ2 neutralizing
antibody (p < 0.01). Addition of PGE2 lead to an 80% reduction in α-SMA expression compared to untreated HLF (p < 0.01).
Figure 7 Expression of α-SMA in HLF co-cultured with either healthy BEC or asthmatic BEC in the presence of TGFβ2 monoclonal
neutralizing antibody. Expression of α-SMA by HLF was greater than both HLF-healthy BEC and HLF asthmatic BEC co-cultures. HLF-asthmatic
BEC co-cultures demonstrated 40% greater expression of α-SMA compared to HLF-healthy BEC co-cultures (p < 0.01). Addition of TGFβ2 neutralizing
antibody did not significantly change α-SMA expression in HLF-healthy BEC co-cultures; however, similar treatment lead to a 30% reduction in the
expression of α-SMA in HLF-asthmatic co-cultures (p < 0.01).
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Figure 8 Expression of tropomyosin-I following 96 hours of co-culture. Expression of tropomyosin-I by HLFs cultured alone was not significantly
different than by HLFs co-cultured with healthy BECs. Tropomyosin expression by HLFs co-cultured with asthmatic BECs was 4.3-fold higher than by
HLFs co-cultured with healthy BECs (p = 0.03) and 6.2-fold greater than HLF alone (p < 0.004).
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that the epithelial cells of the airway exert regulatory in-
fluence on the other cell types of the airway. The find-
ings are significant in the context of asthmatic airway
remodeling and may provide further insight into the
pathophysiology behind the increased airflow obstruc-
tion observed in this population. Furthermore, this study
adds additional evidence to the paradigm that airway
epithelium influences the behavior of other cells types in
the epithelial-mesenchymal unit.
A consistent finding in both studies of adult and
pediatric asthma is the occurrence of sub-epithelial fi-
brosis and deposition of ECM [9,10]. The matrix depos-
ition that occurs in these subjects is largely comprised of
collagens, fibronectin and other ECM constituents that
are deposited by mesenchymal cells such as fibroblasts.
Fibroblasts may arise from multiple different lineages
(reviewed in Hu and Phan 2013, [26]); however, they are
normally present within multiple tissues including lung
and respond to a variety of signals associated with tissue
damage to proliferate and undergo FMT. In contrast,
myofibroblasts are not typically found in healthy tissue,
but arise in response to signaling associated for tissue
damage and wound repair. Myofibroblasts are identifi-
able from resident fibroblasts by the expression of α-
SMA and are known to be a predominant source of type
I collagen and respond to multiple pro-fibrotic and in-
flammatory cytokines including TGFβ [27,28]. The role
of TGFβ in driving FMT is well established and has been
tied to the enhanced production of collagen associatedwith the acquisition of the myofibroblast phenotype [18].
Regulation of the transition to a myofibroblast pheno-
type is complex and has been shown to involve several
signaling pathways including Wnt, Notch, and Hedgehog
in addition to TGFβ and associated downstream media-
tors of these respective pathways [26]. Suppression of α-
SMA gene expression has been shown to be associated
with decreased expression of collagen production estab-
lishing a direct link between the myofibroblast pheno-
type and collagen production [29]. While the presence
of myofibroblasts is essential for the deposition of ECM
and wound contracture in normal wound healing, over
activation can lead to disordered wound repair, hyper-
trophic scarring, and fibrosis [27,30].
Holgate and others have proposed that the airway epi-
thelium is central to asthma pathogenesis and may also
be a driving force behind that the airway remodeling
that is incurred by asthmatic subjects [7]. In this para-
digm, epithelial cells sustain repeated insults through
interaction with environmental factors such viruses, dust
mites, pollen, and other infections that result in recruit-
ment of inflammatory cells leading a chronic wound
state. The latter process invokes endogenous repair mech-
anisms through the production of cytokines and growth
factors that orchestrate wound repair via interactions with
other cell types such as fibroblasts. However, in the case of
asthma, the repair of the epithelium is hypothesized to be
incomplete or dysregulated, resulting in the loss of epithe-
lial tight junctions, which consequently leads to a chronic
wound state and persistence of the factors underlying
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changes imposed by airway remodeling [31,32].
Intracellular signaling between BECs and HLF has been
previously demonstrated in other models. Lama and col-
leagues demonstrated that murine fibroblasts grown alone
in cell culture exhibited increased cellular proliferation
compared to those grown in co-culture with murine
AECs. Using cells derived from transgenic mice, these in-
vestigators additionally linked the down regulation of cells
grown in co-culture to the COX-2 pathway and the pro-
duction of the anti-proliferative signaling of PGE2 [33].
Hostettler and colleagues demonstrated a ~50% reduction
in fibroblast proliferation following incubation of cultured
HLF cells with conditioned media obtained from BECs
[34]. Noteworthy, pre-incubation with a PGE2 inhibitor
negated this effect. In the same series of experiments the
authors demonstrated that adding TGFβ neutralizing anti-
bodies to the conditioned media also blocked the inhibi-
tory effect and concluded that TGFβ was likely involved in
the regulation of the PGE2 axis. These studies highlight
the important concept that is that crosstalk between the
BECs and fibroblast cells may impact FMT and subse-
quent airway repair or remodeling. Additional studies have
highlighted the effects of fibroblasts on AEC proliferation;
however, our study was not designed to investigate this
interaction [35,36].
Recently our group has reported different signaling pro-
files between healthy BECs and asthmatic BECs using our
BEC-HLF co-culture model [11]. In those series of experi-
ments, both healthy and asthmatic subject derived BEC
were differentiated at an ALI and subsequently co-cultured
with a common HLF cell line. Analysis of the media
following 96 hours of co-culture revealed significantly
greater amounts of TGFβ2 in the asthmatic BEC-HLF
co-cultures. In contrast, prostaglandin E2 (PGE2) syn-
thase gene expression was diminished in the asthmatic
BEC-HLF co-cultures. These findings correlated with
an increased expression of several ECM components by
the HLF including collagen types I and III, hyaluronan,
and fibronectin. Thus, these findings support a shift in
the balance of signaling mediators toward a more pro-
fibrotic milieu. The findings of the present study extend
the these findings by demonstrating a diminished regu-
lation of FMT in the asthmatic BEC-HLF co-cultures
suggesting that the enhanced production of ECM com-
ponents is related to an increased presence of myofi-
broblasts in the asthmatic BEC co-cultures. In addition,
the use of TGFβ2 Mab in the present study further
demonstrates the importance of the TGFβ2 signaling
pathway in regulation of FMT. Thus, targeted disruption
of the signaling that facilitates FMT may have direct impli-
cations for the regulation of ECM deposition in this model
system as well as asthmatic airway remodeling and will be
the focus of future investigations.Our study design does have some inherent limitations.
The population of subjects with asthma exhibited mild
airflow obstruction, which is consistent with milder phe-
notypes of asthma. This finding may be independent of
treatment or could alternatively be related to good ad-
herence to controller medications given that 90% of the
asthmatics studied were taking daily ICS at the time of
enrollment. Since the cells used in the co-cultures were
multiple passages beyond the initial sample collection it
is unlikely that any medications being taken at the time
of recruitment would still be present in the culture
media or within the cells themselves. However, we can
not exclude the possibility that the exposure to medica-
tions such as ICS, bronchodilators, or leukotriene re-
ceptor modulators might alter gene expression via
epigenetic or other lasting genetic regulatory mecha-
nisms as information on the occurrence of such processes
in humans is lacking. If present, these effects would likely
bias toward the null hypothesis and make differences in
BEC regulation of FMT between the groups less apparent.
Our asthmatic subjects had significantly lower FEV1/FVC
ratios than the healthy subjects, indicating the presence of
some degree of airflow obstruction despite a relatively
mild asthma phenotype. An additional limitation to our
cohort is that the number of males and females is unbal-
anced. With the relatively small number of subjects in
each group, it is difficult to make meaningful comparisons
between male and female subjects. Given the findings of
the present study in conjunction with our previously
reported findings, additional investigation of signaling
pathways and the balance between pro-fibrotic and anti-
fibrotic signaling pathways is warranted in future studies.
Such investigation may lead to a better understanding of
how FMT may contribute to the disordered wound repair
and abnormal deposition of ECM seen in asthmatic airway
remodeling. This is complicated by challenges involved in
identifying a specific myofibroblast marker. The topic of
which array of markers identify this cell type has been an
area of debate in the pulmonary fibrosis literature for
some time. Most investigators acknowledge that α-SMA is
highly correlated with the myofibroblast phenotype;
however, the specificity of markers is variable [17,26].
In the present study we chose α-SMA expression as
our marker of FMT and evaluated its expression using
multiple techniques. We chose to evaluate the expres-
sion of tropomyosin-I as an additional marker that
could be evaluated by gene expression analysis. We ob-
served that similar to α-SMA expression tropomyosin-I
expression was increased following co-culture with
asthmatic BEC compared to healthy BEC. Interestingly,
we did not observe increased expression of tropomyosin-I
in the HLF that were cultured alone suggesting that there
may not be a 1:1 link between the expression of these two
markers of FMT or that they are governed by different
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mechanisms is beyond the scope of the present study, but
will be an important consideration for future investigation.
Another limitation of this study is that our model is
an in vitro model of cellular function; however, similar
in vivo studies in healthy and asthmatic children would
not be ethical or feasible. The findings from studies such
as these should be verified in animal models of asthma.
The latter may allow for more mechanistic studies to
identify important signaling axes. Despite these limitations
our study design does have several inherent strengths. We
have used a common healthy donor HLF cell line for the
experiments, which helps to isolate differences seen
between the healthy and asthmatic groups to activity of
the BECs. This limits the biologic variability of the HLFs;
however, it is important to point out that our HLF are also
human cells, which are subject to inherent genetic vari-
ability. Our experimental design highlights the differences
between the healthy and asthmatic derived BECs, thus
exploration of the effects of alterations within the HLF is
not possible in the current study. Future studies to dem-
onstrate reproducibility and explore alterations intrinsic to
HLF, i.e. healthy vs. asthmatic derived HLF, will be needed.
Furthermore, we are able to clinically characterize our
population based on medical history, laboratory testing,
and lung function, allowing for strict inclusion and exclu-
sion criteria of the study subjects.Conclusions
In this study, we have demonstrated that HLF cells
from a common healthy donor behave differently when
co-cultured with BECs obtained from a healthy donor
than when co-cultured with BECs obtained from an
asthmatic donor, suggesting that intracellular signaling
between the these two cell populations is important for
the regulation of HLF phenotype. Our finding that
HLFs co-cultured with BECs derived from asthmatic
subjects display a measurably greater degree of FMT
compared to those co-cultured with BECs derived from
healthy subjects may explain the greater degree of sub-
epithelial ECM deposition that has been described pre-
viously in biopsy specimens from asthmatics [9,10].
Furthermore, this finding is also consistent with our
previous report of enhanced ECM deposition in similar
co-culture experiments. Future studies aimed at the
delineation of the signaling mechanisms underlying the
intracellular crosstalk between BECs and HLF, particu-
larly those underlying the differentiation of myofibro-
blasts, are warranted and may provide additional
insight into the development of airway remodeling in
childhood asthma and help identify new therapeutic
targets to prevent remodeling and declines in lung
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